Please check your internet connection and try again.
# Mylotarg (gemtuzumab ozogamicin)
## Overview
Mylotarg is an antibody-drug conjugate that targets CD33, a protein expressed on the surface of acute myeloid leukemia (AML) cells. It is indicated for the treatment of certain adult patients with newly diagnosed AML and relapsed or refractory AML.
## Primary Indications
* **Newly Diagnosed Acute Myeloid Leukemia (AML):** In combination with chemotherapy for adult patients with newly diagnosed AML who are at least 17 years of age.
* **Relapsed or Refractory AML:** For adult patients with relapsed or refractory AML who are at least 17 years of age.
## Adult Dosing
**Newly Diagnosed AML (in combination with chemotherapy):**
* **Cycle 1:** 6 mg/m² on Day 1, Day 4, and Day 7 of induction chemotherapy.
* **Cycle 2 (if applicable):** 6 mg/m² on Day 1 of consolidation chemotherapy.
* **Subsequent Cycles:** 3 mg/m² on Day 1 of subsequent consolidation or maintenance therapy.
**Relapsed or Refractory AML:**
* **Course 1:** 6 mg/m² on Day 1. If there is evidence of disease control, a second course may be administered 2-3 weeks later: 3 mg/m² on Day 1.
* **Maximum cumulative dose:** 27 mg/m².
## Pediatric Dosing
Mylotarg is not approved for use in pediatric patients.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution. If bilirubin is >2.5 mg/dL or AST is >3 times the upper limit of normal, consider delaying or reducing the dose. Consult specific institutional guidelines.
* **Renal Impairment:** No dose adjustment is typically recommended for mild to moderate renal impairment. Use with caution in severe renal impairment.
## Contraindications
* None specifically listed, but caution is advised in patients with hypersensitivity to gemtuzumab ozogamicin or any excipients.
## Adverse Effects
* **Common:** Febrile neutropenia, nausea, vomiting, diarrhea, mucositis, headache, fatigue, rash, myelosuppression (anemia, thrombocytopenia, neutropenia).
* **Serious:** Hepatotoxicity (including veno-occlusive disease/sinusoidal obstruction syndrome), infusion reactions, hemorrhagic events, QT prolongation, tumor lysis syndrome.
## Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Gemtuzumab ozogamicin is metabolized by various enzymes, but specific clinically significant interactions with strong CYP3A4 inhibitors or inducers are not well-defined. Monitor for potential altered toxicity or efficacy.
* **Other Myelosuppressive Agents:** Concomitant use with other myelosuppressive chemotherapy can potentiate myelosuppression.
## Monitoring
* **Complete Blood Counts (CBC):** Regularly monitor for myelosuppression.
* **Liver Function Tests (LFTs):** Monitor for hepatotoxicity, particularly bilirubin and AST/ALT.
* **Infusion Reactions:** Monitor vital signs during and after infusion.
* **Signs of Bleeding:** Monitor for any signs of hemorrhagic events.
* **Renal Function:** Monitor electrolytes and renal function.
* **ECG:** Monitor for QT prolongation, especially in patients with risk factors.
## Clinical Pearls
* Administer as a 30-60 minute intravenous infusion.
* Premedication with an antihistamine, corticosteroid, and antipyretic may be considered to reduce the risk of infusion reactions.
* Hepatotoxicity, particularly VOD/SOS, is a serious and potentially fatal adverse event. Monitor LFTs closely and be aware of the risk factors.
* Hemorrhagic events can occur, especially in patients with severe thrombocytopenia.
* The maximum cumulative dose should not be exceeded.
***
*Disclaimer: This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the current prescribing information and relevant clinical guidelines before making any treatment decisions.*
